Cargando…

De-Escalating the Management of In Situ and Invasive Breast Cancer

SIMPLE SUMMARY: De-escalation of breast cancer treatment reduces morbidity and toxicity for patients. De-escalation is safe if cancer outcomes, such as recurrence and survival, remain unaffected compared to more radical regimens. This review provides an overview on treatment de-escalation for ductal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angarita, Fernando A., Brumer, Robert, Castelo, Matthew, Esnaola, Nestor F., Edge, Stephen B., Takabe, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559495/ https://www.ncbi.nlm.nih.gov/pubmed/36230468 http://dx.doi.org/10.3390/cancers14194545

Ejemplares similares

Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
por: Gupta, Ravi Kumar, et al.
Publicado: (2022)

Behind the clock: elucidating factors contributing to longer clinic appointment duration and patient wait time
por: Kagedan, Daniel Jonathan, et al.
Publicado: (2021)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
por: Murthy, Vijayashree, et al.
Publicado: (2021)

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival
por: Oshi, Masanori, et al.
Publicado: (2021)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Management of Male Breast Cancer: The Journey so Far and Future Directions
por: Sabih, Quratulain (Anna), et al.
Publicado: (2021)

De-escalation in breast cancer surgery
por: Shubeck, Sarah P., et al.
Publicado: (2022)

Impact of Environmental Temperature on the Pathological Complete Response and Survival Outcomes of Breast Cancer: A NCDB and SEER study
por: Gupta, Ashish, et al.
Publicado: (2023)

De-escalation of Sentinel Lymph Node Biopsy in Patients With Ductal Carcinoma In Situ
por: Abdulla, Hussain A, et al.
Publicado: (2023)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Breast Cancer Screening: Is There Room for De-escalation?
por: Kim, Leah S., et al.
Publicado: (2022)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Escalation and de-escalation of mechanical circulatory support in cardiogenic shock
por: Bertoldi, Letizia F, et al.
Publicado: (2021)

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
por: Bueno Muiño, Coralia, et al.
Publicado: (2022)

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer
por: Gianni, Caterina, et al.
Publicado: (2022)

Patient perspectives on chemotherapy de‐escalation in breast cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2021)

De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies
por: Mehanna, Hisham, et al.
Publicado: (2020)

Carcinoma in situ to invasive breast cancer
por: van Deurzen, Carolien H.M., et al.
Publicado: (2015)

Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer
por: Tsuchida, Junko, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
por: Asaoka, Mariko, et al.
Publicado: (2020)

De-escalating axillary surgery in early-stage breast cancer()
por: Hersh, Eliza H., et al.
Publicado: (2021)

Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2022)

Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis
por: Takahashi, Hideo, et al.
Publicado: (2020)

The Role of Surgical Axillary Staging Prior to Immediate Breast Reconstruction in the Era of De-Escalation of Axillary Management in Early Breast Cancer
por: Svensson, Miriam, et al.
Publicado: (2022)

Intelligent escalator passenger safety management
por: Osipov, Vasily, et al.
Publicado: (2022)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

Artificial intelligence to de-escalate loco-regional breast cancer treatment
por: Pfob, André, et al.
Publicado: (2023)

Incidence of Breast Cancer and Enterococcus Infection: A Retrospective Analysis
por: Cardeiro, Matthew, et al.
Publicado: (2023)

MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer
por: Schulze, Amy, et al.
Publicado: (2020)

The Role of Crohn Disease on Breast Cancer Incidence: A Clinical Analysis
por: Patel, Raina K., et al.
Publicado: (2023)

Escalate and De-Escalate Therapies for Intracranial Pressure Control in Traumatic Brain Injury
por: Battaglini, Denise, et al.
Publicado: (2020)

Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
por: Lee, Sang Yeub, et al.
Publicado: (2023)

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
por: Wei, Zhang, et al.
Publicado: (2012)

Types of Cancer and Research Covered in World Journal of Oncology
por: Takabe, Kazuaki, et al.
Publicado: (2022)

Biomarker Research in World Journal of Oncology
por: Takabe, Kazuaki, et al.
Publicado: (2023)

A flexible count data model to fit the wide diversity of expression profiles arising from extensively replicated RNA-seq experiments
por: Esnaola, Mikel, et al.
Publicado: (2013)

APOBEC3-Mediated RNA Editing in Breast Cancer is Associated with Heightened Immune Activity and Improved Survival
por: Asaoka, Mariko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1lh8acf0uu4ghnn9jutj9nu5me